Biobeat Technologies Names Raymond W. Cohen as Board Chairman

Biobeat Technologies Ltd. has selected Raymond W. Cohen to chair its Board of Directors.

Biobeat developed and has received U.S. Food and Drug Administration (FDA) clearance for an easy-to-apply “patch” device that can collect, record, and transmit patient data to a cloud-based data center for artificial intelligence (AI)-aided analysis and reporting of physiological parameters, including continuous cuffless ambulatory blood pressure (ABPM), Sp0₂, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output.

“We welcome Raymond W. Cohen as our new chairman,” Biobeat Technologies Co-Founder/CEO Arik Ben Ishay said. “Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology.”

Cohen, an accredited public company director and accomplished medical technology executive, has more than four decades of life sciences industry experience. He was co-founder and CEO of publicly traded Axonics Inc., developer of implantable neuromodulation devices that completed its initial public offering in late 2018. Under his leadership, Axonics generated more than $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America, and was acquired by Boston Scientific Corp. in November 2024 for $3.7 billion. In March 2025, Cohen, as chairman of SoniVie Ltd., an Israeli clinical stage renal denervation company, led the sale of SoniVie to Boston Scientific for $600 million.

“Biobeat has accomplished what has been an elusive goal for many—a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital,” Cohen stated. “I look forward to collaborating with the management team to support the company’s mission to change the way patients are monitored.”

Cohen currently serves on the boards of several public and venture capital backed innovative healthcare companies, including Kestra Medical Technologies; InspireMD; RxSight; privately held Nalu Medical as chairman; Archimedes Vascular as chairman; Tulavi Medical as vice chairman; and Spectrum Vascular as an independent director. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.

Biobeat based in Israel with offices in Boca Raton Fla., is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp0₂, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, Biobeat offers a cuff-less small unobtrusive “patch” device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat’s products are 510(k) cleared by the FDA.